US4307108A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for lowering sorbitol levels using spiro-imides
Assignee: Pfizer Inc
•
Filing: 1979-12-26
•
Granted: 1981-12-22
•
Expires: 1999-12-26
Abstract
Abstract A series of spiro-imide compounds and their base salts with pharmacologically acceptable cations are disclosed. These particular compounds are useful in therapy as agents for the control of certain chronic diabetic complications. Preferred member compounds include 2,3-dihydro-spiro-[1H-indene-1,3'-pyrrolidone]-2',5'-dione, 2,3-dihydro-spiro-[1H-indene-2,3'-pyrrolidine]-2',5'-dione, 3,4-dihydro-spiro-[2H-naphthalene-1,3'-pyrrolidine]-2',5'-dione, 3,4-dihydro-spiro-[2H-naphthalene-1,3'-piperidine]-2',6'-dione, 6-chloro-2,3-dihydro-spiro-[4H-1-benzopyran-4,3'-pyrrolidine]-2',5'-dione and 6,7-dihydro-spiro-[5H-benzo(b)thiophene-4,3'-pyrrolidine]-2',5'-dione. Methods for preparing these compounds from known starting materials are provided.
Inventors
- 👤 John L. Belletire
- 👤 Reinhard Sarges
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 22:16
CPC Classifications
C; C07; C07D; C07D221/00; C07D221/02; C07D221/20; C07C; C07C255/00; C07C55/00; C07C55/26; C07C55/30; C07D209/00; C07D209/56; C07D209/96; C07D311/00; C07D311/02; C07D311/04; C07D311/58; C07D333/00; C07D333/50; C07D333/52; C07D333/54; C07D491/00; C07D491/02; C07D491/10; C07D495/00; C07D495/02; C07D495/10
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
136 words
A method for lowering sorbitol levels in the sciatic nerve of a diabetic host, which comprises administering to said host an effective amount of a compound selected from the group consisting of spiro-imides of the formulae: ##STR6## and the base salts thereof with pharmacologically acceptable cations, wherein W is --(CH 2 ) n --; X is hydrogen, chlorine, lower alkyl or lower alkoxy each having up to four carbon atoms; X 1 is hydrogen, fluorine, chlorine, bromine, lower alkyl having up to four carbon atoms, lower alkoxy having up to four carbon atoms or phenyl, with the proviso that when X 1 is fluorine, bromine or phenyl, X is hydrogen; Y is oxygen or sulfur; Z is W, Y or Q wherein Q is oxosulfur or dioxosulfur; m is one; and n is zero or one.
Claim 2
Independent Claim
136 words
A method for lowering sorbitol levels in the sciatic nerve of a diabetic host, which comprises administering to said host an effective amount of a compound selected from the group consisting of spiro-imides of the formulae: ##STR6## and the base salts thereof with pharmacologically acceptable cations, wherein W is --(CH 2 ) n --; X is hydrogen, chlorine, lower alkyl or lower alkoxy each having up to four carbon atoms; X 1 is hydrogen, fluorine, chlorine, bromine, lower alkyl having up to four carbon atoms, lower alkoxy having up to four carbon atoms or phenyl, with the proviso that when X 1 is fluorine, bromine or phenyl, X is hydrogen; Y is oxygen or sulfur; Z is W, Y or Q wherein Q is oxosulfur or dioxosulfur; m is one; and n is zero or one.
Claim 3
Dependent Claim
13 words
The method as claimed in claim 1 wherein the compound administered is 2,3-dihydro-spiro-[1H-indene-1,3'-pyrrolidine]-2',5'-dione.
Claim 4
Dependent Claim
13 words
The method as claimed in claim 1 wherein the compound administered is 2,3-dihydro-spiro-[1H-indene-2,3'-pyrrolidine]-2',5'-dione.
Claim 5
Dependent Claim
13 words
The method as claimed in claim 1 wherein the compound administered is 3,4-dihydro-spiro-[2H-naphthalene-1,3'-pyrrolidine]-2',5'-dione.
Claim 6
Dependent Claim
13 words
The method as claimed in claim 1 wherein the compound administered is 6-chloro-2,3-dihydro-[4H-1-benzopyran-4,3'-pyrrolidine]-2',5'-dione.
Claim 7
Dependent Claim
13 words
The method as claimed in claim 1 wherein the compound administered is 6,7-dihydro-spiro-[5H-benzo(b)-thiophene-4,3'-pyrrolidine]-2',5-dione.
Claim 8
Dependent Claim
39 words
A composition suitable for oral administration comprising a pharmaceutically acceptable carrier and a compound of Formula I or II of claim 1 wherein Z is other than W in an amount effective for the treatment of diabetes-associated chronic complications.
References Cited (Backward Citations)
US3507881A
Cited
US3821383A
Cited
US4147795A
Cited
US4177282A
Cited
US4209527A
Cited
US4235911A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1984-12-21 | 1985-06-22 | 1985-12-22 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1988-12-21 | 1989-06-22 | 1989-12-22 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1992-12-21 | 1993-06-22 | 1993-12-22 | $7700.00 | Window Closed / Lapsed |